ADMA Biologics Jumps 11.6% After Rejecting Culper Short Report

NEW YORK, March 28 —

ADMA Biologics (ADMA) rebounded 11.6% Friday after the plasma-derived immunotherapy company issued a formal denial of allegations published by short seller Culper Research, calling the claims "unsubstantiated, misleading and inaccurate."

The bounce does little to repair the damage accumulated since ADMA's last earnings report, with shares still off ~45.4% from that post-earnings level and trading at $9.25. The timing is particularly sharp: Cantor Fitzgerald downgraded ADMA from Overweight to Neutral one day before the rebuttal landed, cutting its bullish conviction just as the company needed sell-side cover most. At 6.7x forward P/E against $510mn in TTM revenue, ADMA trades cheap by biotech standards — but cheapness alone doesn't neutralize a credible short thesis. Culper's track record, and whether its specific allegations carry regulatory weight, will matter more to the next move than valuation multiples. The post-earnings decline suggests the market was already pricing in fundamental softness before Culper fired; the short report accelerates a debate that was already forming.

The binary setup here is unusually stark. If the SEC or FDA opens an inquiry prompted by Culper's report, the 11.6% bounce evaporates quickly and the stock revisits — or breaks — its post-earnings lows. If ADMA's rebuttal holds and no regulatory follow-through materializes, short covering could push shares meaningfully higher from current levels. The critical watch metric over the next 5–10 trading days is whether additional sell-side analysts revise ratings or price targets in either direction — a cluster of downgrades would confirm the Cantor move was an informed signal rather than coincidental timing. Equally, any silence from regulators after 10 trading days reduces the probability of a formal probe and tilts the near-term risk/reward toward holders. Absent a regulatory trigger, this resolves into a credibility contest between ADMA's management and Culper's research, with the stock as the scoreboard.

For a full fundamental breakdown — earnings estimates, revenue trajectory, and institutional positioning — generate a Basis Report on ADMA at /stock/adma.

Basis Report does not hold positions in securities discussed. This is not investment advice.